NKGN: NKGen Price-to-Revenue Coefficient
Geopolitical risks are disrupting supply chains, yet potential monopoly pricing in Alzheimer's treatment creates high value. The market capitalization-to-revenue ratio confirms these fluctuations, where shows the level of this metric. The innovative cell therapy of NKGen Biotech, Inc. (NKGN) promises stable income due to the chronic nature of the disease and long-term patent protection.
Analytical breakdowns for NKGen (NKGN)
- current price and projected stock value:
- market capitalization information:
- company book value details:
- issuer credit burden and liquidity indicators:
Debt to Capital NKGen Biotech, Inc.|NKGN - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio NKGen Biotech Corp|NKGN - Company Aggregate Debts|Debt to Net Assets Ratio NKGen|NKGN - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings NKGen Biotech|Interim Coverage Ratio nkgenbiotech.com
- earnings and multiples data:
NKGN - Company Net Income|Net Profit Forecast NKGen Biotech, Inc.|NKGN - P/E Multiple|Projected Price to Earnings NKGen Biotech Inc|NKGN - Price/Earnings to Growth Multiple|Total Company Value to Operating Income Before Depreciation Ratio NKGen|NKGN - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months NKGen Biotech|NKGN - Earnings per share for the last twelve months|Quarterly EPS earnings growth nkgenbiotech.com|NKGN - Earnings growth in current year|Net earnings per one share growth forecast for next year NKGen Biotech, Inc.
- sales revenue and business income indicators:
General company analysis:nkgenbiotech.com, NKGN
When constructing a long-term portfolio, fundamental screening requires assessing an asset's market value relative to its ability to generate cash flow. The P/S ratio compares market capitalization to annual sales volume, which is critical for NKGen Biotech, Inc. (NKGN), as its unique cell therapy for Alzheimer's disease establishes a foundation for long-term patent revenues, reflecting investment potential through the P/S ratio chart.
Who NKGen Biotech, Inc. competes with
Price-to-Revenue Ratio BIIB (biogen.com)|P/S Multiple NBIX (Neurocrine Biosciences, Inc.)|Price-to-Revenue Coefficient Regencell Bioscience Ltd (RGC)|AXSM - Price-to-Revenue Ratio|Price to Sales ACADIA Corp|XENE (Xenon Pharmaceuticals) - Market Cap to Revenue|VKTX: Market Cap to Sales Volume|SUPN (Supernus) - P/S Multiple|Price to Sales Catalyst Pharma CPRX|P/S Multiple DNLI|Market Cap to Revenue Harmony Corp HRMY|P/S Multiple BHVN (Biohaven Ltd.)|Market Capitalization-to-Revenue Ratio AMLX|TRVI: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio PRAX (Praxis Precision Medicines Inc)|AVXL: P/S Multiple|CBLL - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Prothena Biosciences|Market Cap to Revenue Ratio ALEC (Alector Therapeutics)|P/S Multiple ANNX|Market Cap to Revenue omeros.com OMER|Neurogene Corp - Market Cap to Revenue|Price-to-Revenue Coefficient AC Immune Inc (ACIU)|VYGR - Price-to-Revenue Ratio|NMRA (neumoratx.com) - Market Cap to Revenue Ratio|Scilex (SCLX) - Price-to-Revenue Ratio|Tevogen Bio Holdings Inc. (TVGN) - P/S Multiple|ACOG (Alpha Cognition Inc) - P/S Multiple|CGTX - Price-to-Revenue Multiple|Price-to-Revenue Ratio Inhibikase Therapeutics (IKT)|cassavasciences.com - Market Cap to Revenue Ratio|Price-to-Revenue Ratio Assertio ASRT|COYA: Market Cap to Revenue Ratio|VistaGen Therapeutics Inc - P/S Multiple|Price to Sales Ovid Therapeutics Inc.|ABOS (Acumen Pharmaceuticals) - Market Cap to Revenue|cervomed.com (CRVO) - P/S Multiple|Price-to-Revenue Ratio Alterity Therapeutics Ltd.|CLNN: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio PepGen Inc. (PEPG)|JUNS - Price to Sales|Price-to-Revenue Ratio Relmada Therapeutics RLMD|ANVS: Market Cap to Revenue Ratio|GRCE - Price-to-Revenue Ratio|AIFF - P/S Multiple|KLTO: P/S Multiple|Price-to-Revenue Multiple NeuroSense Therapeutics Ltd. NRSN|RVPH (Reviva Pharmaceuticals) - P/S Multiple|Price to Sales MetaVia, Inc. MTVA|Price-to-Revenue Ratio NeurAxis (NRXS)|heliusmedical.com - Market Cap to Revenue Ratio|Passage Bio - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio NEUP|Minerva Neurosciences - P/S Multiple|ATHA: Price-to-Revenue Ratio|ADXN: P/S Multiple|ALZN - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Cyclerion Therapeutics Inc.|Price to Sales Protagenic PTIX|Market Cap to Revenue KTTA (Pasithea Therapeutics)|Market Cap to Sales Volume CRGT|P/S Multiple ATXI (Avenue Therapeutics, Inc.)|Brainstorm Cell Therapeutics Inc. (BCLI) - Price to Sales|Cara Therapeutics, Inc - P/S Multiple|Chromocell (CHRO) - Market Cap to Revenue|ELYM: P/S Multiple|Intra-Cellular Therapies, Inc. - Market Capitalization-to-Revenue Ratio|Market Cap to Revenue LBPH|MRNS: Market Capitalization-to-Revenue Ratio|P/S Multiple NRBO|Price-to-Revenue Coefficient Sage Therapeutics Inc|Price-to-Revenue Ratio Synaptogenix, Inc. SNPX|TRVN: Market Cap to Revenue Ratio|Vigil Neuro - P/S Multiple|anewmeds.com (WENA) - Market Cap to Revenue|CERE (Cerevel) - Market Cap to Revenue
